How much funding has Mersana raised?

Mersana has raised $103.0M in total funding, most recently a Series C round.

Who are Mersana's investors?

Mersana's investors include Wellington Management, NEA, Pfizer Ventures.

Where is Mersana headquartered?

Mersana is headquartered in Cambridge, Massachusetts, United States.

What industry is Mersana in?

Mersana operates in Antibody Drug Conjugates, Biotech, Healthcare, Life Sciences.

Mersana

Closed

Cambridge, United States · Founded 2001 · $103.0M raised

Antibody Drug Conjugates

Biotech

Healthcare

Life Sciences

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2001
Business Model: B2B

Website: ir.mersana.com
Total Funding: $103.0M
Last Round: $33.0M Series CJun 2016
Rounds: 5

About

Mersana Therapeutics was a clinical-stage biopharmaceutical company focused on next-generation antibody-drug conjugates (ADCs) for cancer treatment, using its proprietary Dolasynthen and Immunosynthen ADC platforms. The company developed Emi-Le (emiltatug ledadotin), targeting B7-H4, for triple-negative breast cancer and other rare cancers. Mersana was acquired by Day One Biopharmaceuticals in January 2026.

Summary

Mersana is an Antibody Drug Conjugates company based in Cambridge, United States, founded in 2001. It has raised $103.0M in total across 5 rounds, most recently a $33.0M Series C round in Jun 2016. Investors include Wellington Management, NEA and Pfizer Ventures.